SCHEMBL22186481

SCHEMBL22186481

Cc1cc(C)cc(CC(C)(C)C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ LMNA P02545 2/20 0.44
▸ TPMT P51580 1/20 0.43
▸ CYP2C9 P11712 3/20 0.42
▸ CYP1A2 P05177 3/20 0.39
▸ TDP1 Q9NUW8 3/20 0.39
▸ PPARA Q07869 2/20 0.39
▸ ADRA1A P35348 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ TTR P02766 1/20 0.39
▸ CYP2C8 P10632 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SLCO1B3 Q9NPD5 1/20 0.39
▸ CISD1 Q9NZ45 1/20 0.39
▸ SLCO1B1 Q9Y6L6 1/20 0.39
▸ GUCY1A1 Q02108 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692554 0.83 CTBP2 (0.49) KDM4EL3MBTL1LMNACYP2C9TDP1
SCHEMBL563644 0.83 PARP10 (0.42) KDM4EL3MBTL1TPMTCYP1A2TDP1
SCHEMBL4457891 0.81 BLM (0.47) KDM4EL3MBTL1CYP2C9CYP1A2TDP1
SCHEMBL19182702 0.79 KDM4E (0.41) KDM4EL3MBTL1LMNACYP2C9CYP1A2
SCHEMBL14740848 0.77 CYP1A2 (0.45) KDM4EL3MBTL1LMNACYP1A2TDP1
SCHEMBL11259816 0.76 ALDH1A1 (0.59) KDM4ELMNACYP2C9CYP1A2TDP1
SCHEMBL20032520 0.76 CNR2 (0.42) KDM4EL3MBTL1PGK1PGK2MAPT
SCHEMBL517462 0.76 SMN1; SMN2 (0.57) LMNACYP2C9CYP1A2PPARAPPARG
SCHEMBL29368049 0.75 CYP1A2 (0.44) KDM4EL3MBTL1LMNACYP1A2TDP1
SCHEMBL22921518 0.75 PPARA (0.48) KDM4EL3MBTL1CYP2C9CYP1A2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020139636-A1 (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER NEXYS THERAPEUTICS, INC. (US) 2020-07-02 — — WO disclosed
Send feedback